OMASIEL COMRIE-REINERT: Open Payments
NPI 1649721713 · LANCASTER, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,034 in 16 payments from 8 companies in 2025. Trend: 2023 $966 · 2024 $2,327 · 2025 $1,034
Food & beverage: $1,034
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 2 | $250 |
| Neurocrine BioSciences, Inc. | 2 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $148 |
| Supernus Pharmaceuticals, Inc. | 3 | $144 |
| E.R. Squibb & Sons, L.L.C. | 3 | $107 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 1 | $69 |
| ABBVIE INC. | 1 | $31 |
Products named: CAPLYTA, Qelbree, AUSTEDO XR, UZEDY, COBENFY, ABILIFY ASIMTUFII, INGREZZA, VRAYLAR.
Industry payments across PA — which companies pay providers there.
